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Not Just Another Cytokine
For two decades, beginning with the ®rst identi®cation of
interleukin-1 (IL-1) in skin, biologists attracted to interests other
than immunity have been bewildered by a growing number and a
confusing nomenclature for the small soluble proteins, cytokines,
that control the lives of leukocytes. Ranging from activation and
proliferation to chemotaxis, these biologically active materials have
grown in number to literally hundreds, with little relief in sight. So,
it is always fair to ask: ``Which ones do we know are important?''
Although those who deal with immunity as a vocation might wish
to say that they all are, investigators in other ®elds would like a little
more data. We can say without equivocation that it is now time for
all who are interested in skin disease to add IL-12 to the obvious
interferons and IL-2. In this issue, Mohamed H. Zaki and six other
investigators from three major investigative centers provide
substantial evidence of a therapeutically useful interaction between
IL-2 and IL-12 (p. 366). IL-2 (T cell growth factor) is already
obvious because of therapeutic trials dating back 10 y for treating
patients with melanoma. But much more recently, IL-12 has been
used therapeutically to treat cutaneous T cell lymphoma, although
the effect apparently wanes as IL-12 receptors are downregulated.
The idea of this study was that IL-2 might retard and even reverse
this downregulation, introducing IL-12 as a truly useful therapy for
this disease. Importantly, this hypothesis was clearly sustained in the
experiments that are reported. We hope that the clinical trials
implied by this observation are either planned or in progress, and
we invite readers to examine this paper and its references with care,
because it is now time for all of us to learn about IL-12.
Genetic Bases for Subsets of Psoriasis
It used to be so simple. Psoriasis was a disease in which the control
of proliferation by keratinocytes was lost (temporarily, at least). As a
young investigator, we searched for chalones, learned about cyclic
AMP, and were teased with the prostaglandins. Twenty years later,
two trends are converging, one anticipated and one unanticipated.
No one is surprised that the proliferation of knowledge about
genetics has had an incredible impact on our understanding of
psoriasis, and with every month, we look expectantly in our
mailbox and on our computer screen for the next chapter. On the
other hand, few could have predicted the recent proliferation of
knowledge about the immunologic features of psoriatic in¯amma-
tion, the possibility of disordered immune regulation, and its
genetic background. Ultimately, however, all of these advances are
going to depend upon the availability and study of clearly de®ned
populations of patients, meaning that clinical observation once
again must come to the fore. This need for astute clinical scholars is
no better demonstrated than in this issue with the paper by
Gudjonsson et al (p. 362). They asked the question whether the
HLA-Cw6 genotype has an effect on the clinical expression
(phenotype) of psoriasis. Indeed, this is the case. Rather than listing
these differences, we leave it to readers to examine their data and at
the same time to re¯ect back on their patients, remembering how
various expressions of psoriasis tended to cluster in families. Indeed,
using a well-de®ned population these investigators have con®rmed
the concept that the genetic background does control the
expression of psoriasis. This knowledge is only one in a series of
steps that may lead to novel, gene-regulating therapies for this still
vexing skin disorder.
A Versatile Factory, the Keratinocyte
One of the ``Holy Grails'' of modern medicine has been to develop
genetically engineered cells that can produce regulated amounts of a
missing protein or of a novel protein with therapeutic activity
in vivo. This would include speci®cally ``tuned'' monoclonal
antibodies directed against any one of a number of targets.
Chances that the keratinocyte might be useful in this respect
seemed dim at ®rst, despite their easy availability and the
considerable experience investigators have had with their culture.
Perhaps the epidermis seemed to be too far from the action; perhaps
the basement membrane would be relatively impermeable to large
proteins. In any event, a more careful look is now in order. In this
issue, NoÈel et al have tested the capacity of normal human primary
keratinocytes to deliver to the systemic circulation an ``ectopic''
antibody (p. 288). Speci®cally, by retroviral gene transduction
in vitro, a monoclonal antibody directed against human thyro-
globulin was placed into keratinocytes. These cells were then used
to construct a ``neo-epidermis'' that was grafted onto immuno-
de®cient mice. Importantly, grafting of this ``engineered'' epider-
mis was followed by sustained antibody production, with delivery
into the blood stream. As the investigators acknowledge in their
discussion, signi®cant hurdles remain before this technology may be
applied to patients. On the other hand, progress toward gene-based
therapies moves forward inexorably. Perhaps the keratinocyte, our
cytokine factory, will take the lead.
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